CC-122, a pleiotropic pathway modulator with activity against DNA-PK, is in Phase 1 trials studying its effects in multiple myeloma, advanced solid tumors, and non-Hodgkin's lymphoma (NCT01421524). Here, PRKDC is linked to AL amyloidosis.